12 Recruiting Ovarian Cancer Phase 3 Clinical Trials
Active phase 3 studies for ovarian cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Ovarian Cancer studiesPhase 3 Studies for Ovarian Cancer
🔵 Active, Not Recruiting Phase3
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
📍 City of Hope — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
📍 Usa Mitchell Cancer Institute /ID# 269661 — Mobile, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
📍 HonorHealth ( Site 0041) — Phoenix, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
D9319C00001- 1L OC Mono Global RCT
📍 Research Site — Santiago,
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
📍 Research Site — Boca Raton, Florida
View Study & Checklist ➔ 🟢 Recruiting Phase3
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
📍 Mt. Sinai Comprehensive Cancer Center — Miami, Florida
View Study & Checklist ➔ 🟢 Recruiting Phase3
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
📍 Mayo Clinic Arizona — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
📍 Site 0107 — Phoenix, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
📍 University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
📍 Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
View Study & Checklist ➔ 🟢 Recruiting Phase3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
📍 Disney Family Cancer Center — Burbank, California
View Study & Checklist ➔